MedTrace Logo

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.

Conditions

Interventions

DRUG

OTT166

Participants will receive OTT166 ophthalmic solution

DRUG

Vehicle control

Participants will receive vehicle control

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • OcuTerra Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Carl Regillo, MD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-29
Primary Completion
2023-12-29
Completion
2023-12-29
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409235 on ClinicalTrials.gov